About The Study: Among patients discharged after hospitalization for heart failure (HF), de novo HF was associated with better clinical and patient-reported outcomes when compared with worsening chronic HF in this randomized clinical trial including 2,858 patients. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.
Authors: Selim R. Krim, M.D., of the Ochsner Clinic Foundation in New Orleans, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2023.4776)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Heart Association’s Scientific Sessions 2023.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2023.4776?guestAccessKey=f131ace0-4733-4b50-be96-1d0808cf5d6f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111323
JAMA Cardiology